<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509286</url>
  </required_header>
  <id_info>
    <org_study_id>P000760</org_study_id>
    <secondary_id>2015-001683-20</secondary_id>
    <secondary_id>DRKS00008008</secondary_id>
    <nct_id>NCT02509286</nct_id>
  </id_info>
  <brief_title>Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus</brief_title>
  <acronym>ESOPEC</acronym>
  <official_title>Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trials Unit Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CTC laboratories at University of Hamburg and University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ESOPEC reference pathology at the University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Leipzig, Universitäres Krebszentrum (UCCL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is designed to investigate differences in outcome of patients with esophageal
      adenocarcinoma and junctional adenocarcinoma treated with perioperative (neoadjuvant +
      adjuvant) chemotherapy (FLOT) plus surgical resection versus neoadjuvant chemoradiation
      (CROSS) plus surgical resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the given evidence a survival benefit of perioperative chemotherapy (periCTX)
      over Neoadjuvant chemoradiation (neoCRT) for patients with Esophageal adenocarcinomas (EAC)
      has not been proven in any randomized controlled trials (RCT). Data supporting the value of
      periCTX have all been obtained in studies including mixed patient cohorts with EAC and
      gastric adenocarcinoma (GAC). Due to relevant differences of histologic subtype distribution,
      response to periCTX and survival rates between EAC and GAC there is a clear need to obtain
      evidence concerning the value of periCTX for EAC. As nowadays periCTX is extensively and
      successfully applied in clinical practice in patients with EAC there is an obvious need to
      obtain evidence from a multicentre RCT. Moreover a confirmation of the superior survival
      rates of the recent RCT on neoCRT should be obtained in a RCT conducted exclusively on EAC.
      Therefore, this prospective RCT with the primary objective of longterm patient survival
      comparing periCTX and neoCRT was designed.

      Translational Projects:

      Project 1+2: Circulating Tumor Cells as Biomarker in EAC CTC laboratories at University of
      Hamburg and University of Freiburg Project 3: Prognostic and predictive biomarkers in EAC
      University of Leipzig, UCCL
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At end of trial- up to 3 years in follow up</time_frame>
    <description>Overall survival will be calculated as time from start of study treatment to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival time (PFS)</measure>
    <time_frame>From randomisation up to 3 years in follow up</time_frame>
    <description>PFS will be calculated as the time interval from randomisation to the first event of locoregional failure, metastatic progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Site of failure: local, regional or distant Failure</measure>
    <time_frame>From time of surgery up to 3 years in follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival time</measure>
    <time_frame>From time of surgery up to 3 years in follow up</time_frame>
    <description>RFS will be calculated in resected patients who achieved an R0 or R1 resection as the time interval from surgery to the date of first recurrence (local, regional or distant) or death, whatever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postsurgical Quality of Life</measure>
    <time_frame>From randomization up to 3 years in follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>From time of surgery up to 90 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-surgical site complications</measure>
    <time_frame>From time of surgery up to 90 days postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">438</enrollment>
  <condition>Esophageal Adenocarcinoma (UICC TNM7)</condition>
  <condition>Adenocarcinoma of the Esophagogastric Junction</condition>
  <arm_group>
    <arm_group_label>Perioperative Chemotherapy (FLOT):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The FLOT Arm consists of the FLOT protocol, which consists of 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel. Repetition every 2 weeks (d15, q2w). Four neoadjuvant cycles (8 weeks) prior to surgery and four adjuvant cycles (8 weeks) postoperatively are given.
Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemoradiation (CROSS):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The CROSS Arm consists of the CROSS protocol, which consists of neoadjuvant radiation therapy (41.4Gy / 23fractions) and concurrent chemotherapy with Carboplatin and Paclitaxel (5 weeks) prior to surgery.
Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>2600 mg/m² (24 hours), d1 every two weeks;</description>
    <arm_group_label>Perioperative Chemotherapy (FLOT):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;</description>
    <arm_group_label>Perioperative Chemotherapy (FLOT):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;</description>
    <arm_group_label>Perioperative Chemotherapy (FLOT):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;</description>
    <arm_group_label>Perioperative Chemotherapy (FLOT):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.</description>
    <arm_group_label>Neoadjuvant Chemoradiation (CROSS):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;</description>
    <arm_group_label>Neoadjuvant Chemoradiation (CROSS):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neoadjuvant radiation</intervention_name>
    <description>41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.</description>
    <arm_group_label>Neoadjuvant Chemoradiation (CROSS):</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically verified adenocarcinoma of the esophagus according to the UICC
             definition (TNM7)

          -  Pre-treatment stage cT1N+, M0 or cT2-4a, N0/+, M0

          -  Age ≥18 years

          -  No prior abdominal or thoracic radiotherapy

          -  ECOG Performance status 0-2

          -  Adequate cardiac function ( Patients with a cardiac history (e.g. myocardial
             infarction, heart failure, coronary artery disease) should have a cardiology review)

          -  Adequate bone marrow function (WBC&gt;3x10^9/l; Hb&gt;9g/dl; platelets &gt;100x10^9/l)

          -  Adequate respiratory function. Symptomatic Patients should have pulmonary function
             tests with FEV1 &gt;65% of predicted)

          -  Adequate renal function (GFR &gt;60ml/min)

          -  Adequate liver function (serum bilirubin &lt;1.5x Upper level of Normal (ULN); AST &lt;2.5x
             ULN and ALT &lt;3x ULN (ULN as per institutional standard)

          -  written informed consent

        Exclusion Criteria:

          -  Tumors of squamous or other non-adenocarcinoma histology

          -  Patients with advanced inoperable or metastatic esophageal adenocarcinoma

          -  Stage cT1N0 and cT4b

          -  Gastric carcinoma

          -  Prior chemotherapy for cancer,

          -  Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery
             disease or myocardial infarction within last 12 months)

          -  Clinical significant lung disease (FEV1 &lt;65% of predicted)

          -  Peripheral neuropathy Grade &gt;1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Hoeppner, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin - Campus Benjamin Franklin (CBF)</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin Campus Virchow-Klinikum (CVK)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt GmbH</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund gGmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>03107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München (LMU)</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruppiner Kliniken GmbH</name>
      <address>
        <city>Neuruppin</city>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Klinikum Offenbach GmbH</name>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.uniklinik-freiburg.de/esopec-studie.html</url>
    <description>ESOPEC Homepage</description>
  </link>
  <reference>
    <citation>Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.</citation>
    <PMID>27435280</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Jens Hoeppner</investigator_full_name>
    <investigator_title>Head of Upper GI Surgery Programm</investigator_title>
  </responsible_party>
  <keyword>Esophageal neoplasms</keyword>
  <keyword>gastro-esophageal junction neoplasms</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>esophagectomy</keyword>
  <keyword>surgery</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

